2014
DOI: 10.1001/jamapsychiatry.2014.163
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia

Abstract: IMPORTANCE In schizophrenia, the severity of negative symptoms is a key predictor of long-term disability. Deficient signaling through the N-methyl-D-aspartate receptor is hypothesized to underlie many signs and symptoms associated with schizophrenia in particular negative symptoms. Glycine acts as an N-methyl-D-aspartate receptor coagonist. Blockade of the glycine transporter type 1 to inhibit glycine reuptake and elevate synaptic glycine concentrations represents an effective strategy to enhance N-methyl-D-a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
126
1
2

Year Published

2015
2015
2024
2024

Publication Types

Select...
8
2

Relationship

2
8

Authors

Journals

citations
Cited by 196 publications
(135 citation statements)
references
References 54 publications
6
126
1
2
Order By: Relevance
“…Beside the dopaminergic system, dysfunctional glutamatergic neurotransmission has strongly been implicated in the etiology of schizophrenia, [1][2][3] particularly a hypofunction of the N-methyl-d-aspartate-receptor (NMDAR). 4 As NMDAR hypofunction is especially associated with negative symptoms, 5 the NMDAR is continuously discussed as being a promising target for the introduction of new medications.…”
Section: Introductionmentioning
confidence: 99%
“…Beside the dopaminergic system, dysfunctional glutamatergic neurotransmission has strongly been implicated in the etiology of schizophrenia, [1][2][3] particularly a hypofunction of the N-methyl-d-aspartate-receptor (NMDAR). 4 As NMDAR hypofunction is especially associated with negative symptoms, 5 the NMDAR is continuously discussed as being a promising target for the introduction of new medications.…”
Section: Introductionmentioning
confidence: 99%
“…It is worth re-iterating that the majority of pharmacological advances in psychiatry have been spurred on by useful serendipity, but in the last 40 years and the current interest in ketamine (as a fast acting antidepressant) notwithstanding (Naughton et al 2014), very few therapeutics with novel mechanisms of action have progressed to phase III clinical trials or regulatory approval (Umbricht et al 2014). Major pharmaceutical companies have shifted drug discovery efforts away from psychiatric towards non-psychiatric disorders with identified biological targets (Miller, 2010).…”
mentioning
confidence: 99%
“…Ek olarak, glutamaterjik düzenleyicilerin yazında çelişen sonuçlar olmasına rağmen daha çok negatif belirtilerde etki gösterdiği bildirilmiştir (Sommer ve ark. 2012, Umbricht ve ark. 2014, Hashimoto ve ark.…”
Section: Discussionunclassified